10,406 Shares in GRAIL, Inc. $GRAL Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in GRAIL, Inc. (NASDAQ:GRAL) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,406 shares of the company’s stock, valued at approximately $710,000.

Several other hedge funds have also bought and sold shares of the stock. Fifth Third Bancorp grew its stake in GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares in the last quarter. N.E.W. Advisory Services LLC purchased a new stake in shares of GRAIL during the 4th quarter valued at $26,000. Comerica Bank raised its position in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after buying an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of GRAIL during the 4th quarter worth $28,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on GRAL shares. Piper Sandler upped their target price on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho upped their price objective on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Robert W. Baird set a $70.00 price objective on GRAIL in a research report on Wednesday, May 6th. Finally, TD Cowen reissued a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $67.78.

Insider Transactions at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the transaction, the insider directly owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.83% of the stock is currently owned by insiders.

GRAIL Stock Performance

Shares of GRAL opened at $73.96 on Thursday. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of -7.59 and a beta of 3.24. The firm has a 50 day moving average price of $68.26 and a 200-day moving average price of $64.38.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. As a group, equities research analysts predict that GRAIL, Inc. will post -10.41 earnings per share for the current year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.